Immunotherapy in triple-negative breast cancer: A literature review and new advances.
World J Clin Oncol
; 13(3): 219-236, 2022 Mar 24.
Article
in En
| MEDLINE
| ID: mdl-35433291
ABSTRACT
Triple-negative breast cancer (TNBC) is a highly complex, heterogeneous disease and historically has limited treatment options. It has a high probability of disease recurrence and rapid disease progression despite adequate systemic treatment. Immunotherapy has emerged as an important alternative in the management of this malignancy, showing an impact on progression-free survival and overall survival in selected populations. In this review we focused on immunotherapy and its current relevance in the management of TNBC, including various scenarios (metastatic and early -neoadjuvant, adjuvant-), new advances in this subtype and the research of potential predictive biomarkers of response to treatment.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
Language:
En
Journal:
World J Clin Oncol
Year:
2022
Document type:
Article